Human Reproduction, Vol. 15, No. 10, 2098-2102,
October 2000
© 2000 European Society of Human Reproduction and Embryology
Prediction models for insulin resistance in the polycystic ovary syndrome
1 Departments of Obstetrics and Gynaecology, 2 Geriatrics, 3 Internal Medicine, Akademiska Hospital, Uppsala University, Uppsala, Sweden and 4 Department of Obstetrics and Gynecology S. Anna Hospital, Torino University, Torino, Italy
Women with the polycystic ovary syndrome (PCOS) have a high prevalence of insulin resistance, with consequent increased risk of metabolic diseases later in life. An early metabolic screening would therefore be of clinical relevance. By using stepwise regression analysis on several variables obtained in 72 women with PCOS, we constructed simple and reliable mathematical models predicting insulin sensitivity, as measured by the euglycaemic hyperinsulinaemic clamp. The normal ranges of insulin sensitivity were calculated from 81 non-hirsute, normally menstruating women with normal ovaries, and similar body mass index (BMI) and age as the women with PCOS. Measured variables included BMI, waist and hip circumferences, truncalabominal skin folds, circulating concentrations of gonadotrophins, androgens, sex hormone-binding globulin (SHBG), triglycerides, total cholesterol and cholesterol subfractions, fasting insulin, C-peptide and free fatty acids. The three best prediction models included waist circumference, together with insulin (model I: R2 = 0.77), serum triglycerides (model II: R2 = 0.65), and the subscapularis skin fold (model III: R2 = 0.64). Using reference limits for insulin sensitivity obtained in the 81 normal pre-menopausal women, the models identify insulin resistant women with PCOS. These simple and inexpensive models are potentially useful in clinical practice as an early screening in women with PCOS.
Key words: euglycaemic hyperinsulinaemic clamp/insulin resistance/PCOS/screening
5 To whom correspondence should be addressed at: Department of Obstetrics and Gynaecology, S. Anna Hospital, Torino University, via Ventimiglia 3, 10126 Torino, Italy.E-mail: gennarelligl{at}libero.it
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gennarelli, V. Rovei, R. F. Novi, J. Holte, F. Bongioanni, A. Revelli, G. Pacini, P. Cavallo-Perin, and M. Massobrio Preserved Insulin Sensitivity and {beta}-Cell Activity, but Decreased Glucose Effectiveness in Normal-Weight Women with the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3381 - 3386. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. De Leo, A. la Marca, and F. Petraglia Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome Endocr. Rev., October 1, 2003; 24(5): 633 - 667. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Legro Polycystic Ovary Syndrome and Cardiovascular Disease: A Premature Association? Endocr. Rev., June 1, 2003; 24(3): 302 - 312. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schachter, A. Raziel, S. Friedler, D. Strassburger, O. Bern, and R. Ron-El Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine Hum. Reprod., April 1, 2003; 18(4): 721 - 727. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Cibula, J. Skrha, M. Hill, M. Fanta, L. Haakova, J. VrbIkova, and J. Zivny Prediction of Insulin Sensitivity in Nonobese Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5821 - 5825. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Vrbikova, B. Bendlova, M. Hill, M. Vankova, K. Vondra, and L. Starka Insulin Sensitivity and {beta}-Cell Function in Women With Polycystic Ovary Syndrome Diabetes Care, July 1, 2002; 25(7): 1217 - 1222. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Yasuhi, J. W. Hogan, J. Canick, M. B. Sosa, and M. W. Carpenter Midpregnancy Serum C-Peptide Concentration and Subsequent Pregnancy-Induced Hypertension Diabetes Care, April 1, 2001; 24(4): 743 - 747. [Abstract] [Full Text] |
||||




